Autosomal Dominant Polycystic Kidney Disease Market Forecast to 2036
2026年 08月 03日
The autosomal dominant polycystic kidney disease market is entering a milestone decade. Better imaging, wider genetic testing, and growing physician awareness are catching more cases earlier, while a thin pipeline of disease-modifying options is finally starting to fill out. Together, these forces are reshaping the polycystic kidney disease treatment market across the seven major markets — the US, Germany, France, Italy, Spain, the UK, and Japan.
Disease Burden and ADPKD Epidemiology
ADPKD, the inherited disorder behind progressive cyst growth and eventual kidney failure, is estimated to affect roughly 1 in 400 to 1,000 people worldwide, giving a sense of the scale of ADPKD incidence globally. Mutations in the PKD1 gene account for roughly 85% of cases and tend to progress faster, while PKD2 accounts for most of the remainder and is generally milder. A smaller share of diagnoses trace to other genes such as IFT140, DNAJB11, and GANAB, and 10–15% of patients have no family history at all — pointing to a meaningful de novo mutation rate.
In terms of ADPKD epidemiology , the US led the seven major markets with around 147,000 diagnosed prevalent cases in 2025, while Italy reported the fewest at roughly 16,500. Japan recorded close to 31,000 diagnosed cases the same year. Disease burden peaks in the 45–64 age bracket, and cardiovascular disease — largely coronary artery disease — remains the leading cause of premature death, underscoring why autosomal dominant polycystic kidney disease prevalence figures alone don't capture the full clinical picture. Looking at market size by geography, the US kidney cyst market remains the largest contributor to the overall kidney cyst market , followed by the UK kidney cyst market , which leads among the EU4 nations, with the Germany kidney cyst market , France kidney cyst market , Italy kidney cyst market , and Spain kidney cyst market rounding out Europe's share. The Japan kidney cyst market also holds a notable slice of the 7MM total, and interest continues to build in adjacent geographies including the India kidney cyst market , South America kidney cyst market , and GCC kidney cyst market , even though formal forecasts there remain limited.
Current Hospitality Center
Tolvaptan — sold as Jynarque, Jinarc, and Samsca — remains the only approved therapy for ADPKD, and its first-in-class status still anchors the autosomal dominant polycystic kidney disease treatment market . As a vasopressin V2-receptor antagonist, it slows kidney function decline in adults at high risk of rapid progression, but a black-box warning for serious liver injury, strict monitoring requirements, and tolerability issues cap its reach. Outside of tolvaptan, management still leans on ACE inhibitors, ARBs, and blood-pressure control — supportive care rather than a cure, which is why the broader polycystic kidney disease drugs market continues to be defined by high unmet need.
Pipeline and Newer Drugs
The PKD treatment pipeline is where the next phase of growth is expected to come from. Calico Life Sciences ADPKD candidate ABBV-CLS-628, a monoclonal antibody targeting PAPP-A, is in Phase II and recently received Fast Track Designation; it's a good example of FDA orphan drug designation 2025 ADPKD activity picking up pace. Novartis' farabursen, a microRNA-17 inhibitor gained through its Regulus Therapeutics acquisition, has shown encouraging Phase Ib biomarker data . diversify a polycystic kidney disease therapeutics market long dominated by a single approved option.
Adjacent and Related Chips
Because kidney-cyst disorders and broader renal conditions overlap clinically, ADPKD forecasts are often read alongside related segments — the acquired cystic kidney disease treatment drugs market , the APOL1 mediated kidney disease market , the nephrotic syndrome market , and even rarer entities like the acro pectoro renal field defect market — each shaping how payers and developers think about renal drug portfolios generally.
Outlook to 2036
With rising polycystic kidney disease incidence and prevalence , an expanding pipeline, and growing KOL and physician engagement, the ADPKD market forecast 2032 and beyond points to steady growth. Whether measuring PKD prevalence trends or the future of polycystic kidney disease care, the direction is clear: disease-modifying, better-tolerated options are what the next decade of this polycystic kidney disease market is being built around.
Latest Reports Offered by Delveinsight
chronic inflammatory demyelinating polyneuropathy market | endometriosis market | eosinophilic esophagitis market | familial amyloid polyneuropathy market | food allergy market | hepatitis c market | holter monitor market | hyperlipidemia market | implantable infusion pump market market | negative pressure wound therapy npwt devices market | nocturia market | rheumatoid arthritis market | spinal fusion devices market | tinnitus market | type 1 diabetes market | alzheimer's disease market | asthma market | brain monitoring devices market | chronic pain market | chronic pancreatitis market | cystic fibrosis market | dry age-related macular degeneration market | gall bladder cancer market | gential herpes market |
About Delveinsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Contact Us
Kanishk
